Publications by authors named "Joey Sze Yun Lim"
Article Synopsis
- The study examined how hepatocellular cancer (HCC) cells behave in more natural, tumor-like conditions (low oxygen and glucose) compared to standard culture conditions.
- HCC cells grown in these native conditions demonstrated distinct differences in growth rates, metabolic profiles, and gene expression, including mutations in mitochondrial DNA and altered sensitivity to drugs.
- The findings suggest that culturing HCC cells under more realistic environmental conditions can lead to a more aggressive cancer phenotype and varied drug responses, potentially aiding in tumor biology research and drug development strategies.
Background: Emergence of drug-resistant cancer phenotypes is a challenge for anti-cancer therapy. Cancer stem cells are identified as one of the ways by which chemoresistance develops.
Method: We investigated the anti-inflammatory combinatorial treatment (DA) of doxorubicin and aspirin using a preclinical microfluidic model on cancer cell lines and patient-derived circulating tumour cell clusters.
Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentially predictive of clinical outcome. The aim of this study was to assess the concordance of reported PD-L1 IHC assays and investigate factors influencing variability. Consecutive sections from 20 non-small cell lung cancers (NSCLCs) comprising resection, core biopsy, cytology and pleural fluid samples underwent IHC with 5 different antibody/autostainer combinations: 22C3/Link48, 28-8/BOND-MAX, E1L3N/BOND-MAX, SP142/BenchMark and SP263/BenchMark.
View Article and Find Full Text PDFObjectives: To characterize the expression of PD-L1, PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and T-cell immunoglobulin and mucin-domain containing-3 (TIM3) in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).
Materials And Methods: Samples from 90 patients with newly diagnosed advanced stage NSCLC harboring EGFR mutations and treated with first line EGFR tyrosine kinase inhibitors (TKI) within 3 months of diagnosis were stained for CTLA-4, PD-L1, PD-1, TIM-3 and CD3 expression by immunohistochemistry.
Results: PD-L1 was present in at least 1% of immune and tumor cells in 44% and 59% of samples, respectively.